Quick Answer
ImageneBio, Inc. reported Cash and Equivalents of $94.53 million for fiscal year 2025.
ImageneBio, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $94.53M | +680.1% |
| 2024 | $12.12M | -89.9% |
| 2023 | $119.89M | +100.1% |
| 2022 | $59.92M | -74.2% |
| 2021 | $232.22M | +42.9% |
| 2020 | $162.49M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $103.16M | +128.3% | +77.0% |
| June 30, 2025 | $58.29M | +31.7% | +58.6% |
| March 31, 2025 | $36.76M | -30.4% | +203.4% |
| December 31, 2024 | $12.12M | -89.9% | -73.2% |
| September 30, 2024 | $45.19M | -62.7% | +2.1% |
| June 30, 2024 | $44.27M | -37.5% | -16.2% |
| March 31, 2024 | $52.85M | +80.2% | -55.9% |
| December 31, 2023 | $119.89M | +100.1% | -1.1% |
- ImageneBio, Inc. showed an increase of +680.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, ImageneBio, Inc.’s cash and equivalents has declined by 41.8% (from $162.49 million to $94.53 million).
- The most recent figure is from ImageneBio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: